# NCT02166463 (NCT02166463)

> Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02166463
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Childhood Hodgkin Lymphoma; Classic Hodgkin Lymphoma
- Interventions: Bleomycin Sulfate; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin Hydrochloride; Etoposide; Laboratory Biomarker Analysis; Methylprednisolone; Pharmacological Study; Prednisone; Quality-of-Life Assessment; Questionnaire Administration; Vincristine Sulfate
- Enrollment: 600
- Primary outcome: Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death

## Commentary we found

- X threads: 8
- YouTube: 3
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct02166463

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02166463", "email": "<work email>"}; the inbox owner confirms by the emailed link.